We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge
News

Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge

Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge
News

Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The patent at issue covers the administration of mesenchymal stem cells (MSCs), including Prochymal® (remestemcel-L), for the treatment of inflammatory conditions involving the gastrointestinal tract, including Crohn’s disease and ulcerative colitis.

As acknowledged in the Australian Official Journal of Patents Supplement, all claims to the patent will be maintained in full. The claims specifically include the use of allogeneic MSCs, an attribute central to making an off-the-shelf MSC product possible.

In 2012, Prochymal, an intravenous formulation of MSCs, became the world's first stem cell drug to gain approval by an internationally recognized regulatory authority. Prochymal is also the first drug approved for acute graft versus host disease (GvHD) - a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis. Prochymal is now approved in Canada and New Zealand, and is currently available in seven other countries including the United States under an Expanded Access Program.

Advertisement